1, reporting the results of just over expectations.
First-half operating income of 3.276 billion yuan, up 13.05% over last year; total profit of 196 million yuan, up 11.19% over last year. Attributable China flexible thermometer manufacturer to shareholders of listed companies net profit of 1.28 billion yuan, up 22.08%, earnings per share were 0.41 yuan, slightly higher than expected results. Better control of costs, expense ratio during the first half year only slightly improved by 0.7 percentage points.
2, the pharmaceutical business continued to grow rapidly.
Sub-industry perspective, the first half of the pharmaceutical business revenue increased 25.22%, 23.86% cost increase, driven by an increase of China pacifier thermometer manufacturer 1 percentage point margin. Pharmaceutical industry and the steady growth of international trade, in the first half revenues were up by 6.21%, 4.07%, respectively, an increase of 4.09,0.5 gross margin percentage points.
3,China basal thermometer enhance the corporate value of overseas orders.
Company announcement, was received on August 3 contract Venezuela advance 59,870.88 million, about $ 9,071 million. Advance the company awarded the contract point a little earlier than we had expected, the cooperation with Venezuela, have a significant role in promoting company performance.
China waterproof thermometer Venezuela is currently the basic medical equipment and medicines were all imported, the annual imports of about 70 billion dollars, the company accounted for the amount of the contract Venezuela imports about 10%. The contract was signed, the company will fully cover the required drugs and medical devices Venezuela, and the lump sum for each other to provide a package of services, the Company received advance payment for the purchase of domestic products primarily to the object, its own OEM, and then sold to Venezuela. Venezuela is a universal health care, China fever thermometer manufacturer all medical-related products and services by the government foot the bill, so we think the agreement of the contract profit margin gross profit margin than the company's traditional business is a high probability event.
4, the integration of assets have been put on the agenda.
Major shareholder is the China General Technology Group Holdings Co., Ltd., major shareholders clearly resolved in 3-5 years, the company's competition with industry, the integration of assets has been put on the agenda. Universal Group is currently the major shareholder with medicine-related assets, medicine, and so there are days of parties, we believe that the future will be the major shareholder's major pharmaceutical companies as a platform for the integration of its assets related to the pharmaceutical companies. We expect the restructuring will be carried out in batches, complete the Group's pharmaceutical assets, integration up to the 2014.
Tip: This article is part of the report, only institutions or a stock analyst's personal views and opinions, not official news, Ben Wang does not guarantee its authenticity and objectivity, all the stock of useful information to Shanghai and Shenzhen Stock Exchange subject to notice, please pay attention to the risk investors.